Karyopharm secures unanimous lender support for prepackaged Chapter 11 restructuring
KPTI•Karyopharm Therapeutics secured support for its proposed prepackaged Chapter 11 plan from holders of 100% of its specified loan, notes and RIFA claims; votes are due November 30, 2026, and the plan requires court confirmation.
1. Creditor support
Karyopharm Therapeutics secured support under a restructuring support agreement for its proposed prepackaged Chapter 11 plan. Supporting holders represent 100% of 1L Term Loan Claims, 1.5L 2028 Notes Claims, 2L 2029 Notes Claims and RIFA Claims.
2. Plan vote
Votes are due November 30, 2026, at 4 p.m. Central Time. The plan requires bankruptcy court confirmation, and allowed general unsecured claims would remain unimpaired.
